K&L Gates Advises Rocket Pharmaceuticals on Public Offering of Common Stock

Global law firm K&L Gates LLP advised Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, in connection with an underwritten public offering of 15,180,000 shares of its common stock at a price to the public of US$12.50 per share. Total proceeds from the offering were US$189.8 million.

Morgan Stanley, Leerink Partners, and Cantor acted as joint book-running managers, and LifeSci Capital acted as lead manager for the offering. The firm also advised Rocket in connection with a concurrent private placement of pre-funded warrants to purchase 400,000 shares of Rocket common stock, at an offering price of $12.49 per pre-funded warrant. Total proceeds from the private placement were US$5.0 million.

The K&L Gates team was led by New York partner Whitney Smith and Charlotte partner Sean Jones. Research Triangle Park partner Mike Hinckle, Wilmington partner Kelly Terribile, New York associate Zidong Liu, and Charlotte associates Jeff Pititto and Lindsey Taulbee assisted on the matter. New York partner Tony Nolan and Boston partner Todd Gibson provided support on legal opinion issues.

K&L Gates’ Corporate practice is one of the most substantial in the legal industry, with hundreds of lawyers in offices on five continents providing clients with practical legal solutions in the structuring, financing, and completion of domestic, international, and cross-border transactions.